Adenosquamous Carcinoma Clinical Trials

3 recruiting

Adenosquamous Carcinoma Trials at a Glance

12 actively recruiting trials for adenosquamous carcinoma are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Oklahoma City, New Brunswick, and Madison. Lead sponsors running adenosquamous carcinoma studies include National Cancer Institute (NCI), Christian Hinrichs, and Diakonos Oncology Corporation.

Browse adenosquamous carcinoma trials by phase

Treatments under study

About Adenosquamous Carcinoma Clinical Trials

Looking for clinical trials for Adenosquamous Carcinoma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Adenosquamous Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Adenosquamous Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 2

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell CarcinomaResectable Pancreatic CarcinomaResectable Pancreatic Adenocarcinoma+4 more
National Cancer Institute (NCI)152 enrolled453 locationsNCT04858334
Recruiting
Phase 2

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

Squamous Cell CarcinomaAdvanced Non-Small Cell Lung CancerAdvanced NSCLC+2 more
National Cancer Institute (NCI)85 enrolled1 locationNCT02133196
Recruiting
Phase 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Locally Advanced Cervical Adenocarcinoma+5 more
National Cancer Institute (NCI)336 enrolled222 locationsNCT07061977
Recruiting
Phase 2

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Pancreatic AdenocarcinomaPancreatic Neuroendocrine TumorGastrointestinal Neuroendocrine Tumor+4 more
University of Michigan Rogel Cancer Center66 enrolled3 locationsNCT05988918
Recruiting
Phase 3

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

Cervical CarcinomaAdenocarcinomaAdenosquamous Carcinoma
Institut Claudius Regaud510 enrolled34 locationsNCT05581121
Recruiting
Phase 3

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.900 enrolled2 locationsNCT07491445
Recruiting
Phase 2

Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda

Cervical CancerCervix CancerCervical Adenocarcinoma+2 more
Uganda Cancer Institute278 enrolled1 locationNCT07276360
Recruiting
Phase 1

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Gastric AdenocarcinomaGEJ AdenocarcinomaPDAC - Pancreatic Ductal Adenocarcinoma+4 more
Avacta Life Sciences Ltd144 enrolled2 locationsNCT07454642
Recruiting
Phase 2

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Cervical CancerMetastatic CancerAnal Cancer+18 more
Christian Hinrichs20 enrolled3 locationsNCT05686226
Recruiting
Phase 1Phase 2

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Cervical CancerAnal CancerPenile Cancer+14 more
Christian Hinrichs15 enrolled2 locationsNCT05639972
Recruiting
Phase 1Phase 2

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma+1 more
Jonsson Comprehensive Cancer Center35 enrolled4 locationsNCT06543576
Recruiting
Phase 1

Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic AdenocarcinomaPancreatic Adenosquamous Carcinoma
Diakonos Oncology Corporation18 enrolled3 locationsNCT04157127